摘要
目的探讨艾司西酞普兰与舍曲林治疗抑郁症的临床疗效和安全性。方法将64例抑郁症患者随机分为两组，每组32例，研究组口服艾司西酞普兰治疗，对照组口服舍曲林治疗，观察6周。于治疗前及治疗第1周、2周、4周、6周末采用汉密顿抑郁量表、临床总体印象量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组汉密顿抑郁量表、临床总体印象量表评分较治疗前有显著下降（P〈0．01）；研究组治疗1周末较对照组下降更显著（P〈0．05或0．01），其他时段评分两组差异均无显著性（P〉0．05）。治疗6周末研究组总有效率93．8％，对照组为90．6％，两组差异无显著性（P〉0．05）。两组不良反应均轻微，发生率差异无显著性（P〉0．05）。结论艾司西酞普兰与舍随林治疗抑郁症疗效均显著，且安全性高，依从性好，但艾司西酞普兰较舍曲林起效更快，更有利于提高患者的治疗依从性。
Objective To explore the efficacy and safety of escitalopram vs sertraline in the treatment of depression. Methods Sixty-Forth depression patients were randomly divided into two groups of 32 each, research group took orally escitalopram and control group did sertraline for 6 weeks. Efficacies were as- sessed with the Hamilton Depression Scale （HAMD） and Clinical Global Impression （CGI） and adverse re- actions with the Treatment Emergent Symptom Scale （TESS） before treatment and at the end of the 1st, 2nd, 4th and 6th week. Results After treatment the HAMD and CGI scores of both groups lowered more significantly compared with pretreatment （P〈0.01） ; at the end of the 1st week the HAMD and CGI scores lowered more significantly in research than in control group （P〈0.05 or 0.01）, there were no significant group differences in other periods （P〉0.05）. At the end of 6th week, there was no significant difference in total effective rate between research and control group （93.8% vs90.6%,P〉0.06）. Adverse reactions of both groups were mild and there were no significant group difference in the incidences of adverse reactions （P〉0.05）. Conclusion Both escitalopram and sertraline have an evident effect,higher safety and better compliance, but the former takes effect more rapidly and is more suitable for improving patients＇ compli- ance.
出处
《临床心身疾病杂志》
CAS
2012年第5期424-425,共2页
Journal of Clinical Psychosomatic Diseases
